4.6 Review

Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria

Journal

INTENSIVE CARE MEDICINE
Volume 41, Issue 5, Pages 776-795

Publisher

SPRINGER
DOI: 10.1007/s00134-015-3719-z

Keywords

Antibiotic; Bacteria; Resistance; MRSA; Stewardship

Funding

  1. Algorithm
  2. Angelini
  3. Astellas Pharma Inc.
  4. AstraZeneca
  5. Cubist
  6. Pfizer MSD
  7. Gilead Sciences
  8. Novartis
  9. Ranbaxy
  10. Teva
  11. Astellas
  12. Gilead
  13. MSD
  14. Pfizer
  15. Bayer
  16. Actavis
  17. GSK
  18. Medicines Co.
  19. Merck
  20. Tetraphase
  21. Abbott Laboratories
  22. Actelion
  23. Astra-Zeneca
  24. Cerexa
  25. Durata
  26. European Tissue Symposium
  27. Medicines Company
  28. MedImmune
  29. Motif Biosciences
  30. Nabriva
  31. Optimer
  32. Paratek
  33. Roche
  34. Sanofi-Pasteur
  35. Seres
  36. Summit
  37. Synthetic Biologics
  38. Abbott
  39. Alere
  40. bioMerieux
  41. Da Volterra

Ask authors/readers for more resources

The antibiotic pipeline continues to diminish and the majority of the public remains unaware of this critical situation. The cause of the decline of antibiotic development is multifactorial and currently most ICUs are confronted with the challenge of multidrug-resistant organisms. Antimicrobial multidrug resistance is expanding all over the world, with extreme and pandrug resistance being increasingly encountered, especially in healthcare-associated infections in large highly specialized hospitals. Antibiotic stewardship for critically ill patients translated into the implementation of specific guidelines, largely promoted by the Surviving Sepsis Campaign, targeted at education to optimize choice, dosage, and duration of antibiotics in order to improve outcomes and reduce the development of resistance. Inappropriate antimicrobial therapy, meaning the selection of an antibiotic to which the causative pathogen is resistant, is a consistent predictor of poor outcomes in septic patients. Therefore, pharmacokinetically/pharmacodynamically optimized dosing regimens should be given to all patients empirically and, once the pathogen and susceptibility are known, local stewardship practices may be employed on the basis of clinical response to redefine an appropriate regimen for the patient. This review will focus on the most severely ill patients, for whom substantial progress in organ support along with diagnostic and therapeutic strategies markedly increased the risk of nosocomial infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available